Related Experiment Video
Updated: Sep 11, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab
Ken Yamamoto1, Katsuya Hirano1, Temiko Shimada1
1Division of Thoracic Oncology, Kobe Minimally Invasive Cancer Center, Kobe, Japan.
Abstract:
Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is a major irAE of the chimeric antigen receptor T-cell therapy and a rare irAE for anti-programmed cell death protein-1 and programmed death-ligand 1 therapy. Therefore, reports of CRS were rare in NSCLC, but after approval of anti-programmed cell death protein-1 and anti-programmed death-ligand 1 plus anti-CTLA-4 antibodies, reports of CRS are increasing. We, here, report two cases of successful tocilizumab treatment for steroid pulse-refractory CRS in chemotherapy with durvalumab plus tremelimumab for NSCLC.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...